Clinical trial
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)
NCT05495152 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: a Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)
- Lead sponsor
- Henan Cancer Hospital
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 1, 2022
- Completion date
- August 31, 2028
- Enrollment
- 219 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.